Payment overview · 2025
General Payments
$145.05
7 reported records · 5 companies
Healthcare provider profile · identity verified
Lisa Morris, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · JACKSON, TN · NPI 1720732175
Verified facts
What the public records show
CMS Open Payments records show Lisa Morris, NP received $145.05 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 46.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $67.75 | 46.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.19 | 18.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.56 | 13.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.45 | 10.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.10 | 10.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $145.05 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $67.75 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $27.19 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.19 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 208 | 21 |
| Gabapentin | Gabapentin | 166 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 134 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 33 |
| Alprazolam | Alprazolam | 130 | 22 |
| Omeprazole | Omeprazole | 122 | 37 |
| Lisinopril | Lisinopril | 110 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 109 | 32 |
| Methocarbamol | Methocarbamol | 99 | 34 |
| Simvastatin | Simvastatin | 98 | 29 |
| Buspirone Hcl | Buspirone Hcl | 96 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 42 |
| Meloxicam | Meloxicam | 91 | 23 |
| Losartan Potassium | Losartan Potassium | 90 | 23 |
| Ozempic | Semaglutide | 85 | 16 |
| Atorvastatin Calcium | Atorvastatin Calcium | 83 | 23 |
| Celecoxib | Celecoxib | 80 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | suppressed |
| Furosemide | Furosemide | 70 | 22 |
| Clonazepam | Clonazepam | 69 | 12 |
| Metformin Hcl | Metformin Hcl | 69 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 69 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 11 |
| Potassium Chloride | Potassium Chloride | 65 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 64 | 16 |
| Azelastine Hcl | Azelastine Hcl | 63 | 42 |
| Ondansetron Odt | Ondansetron | 63 | 32 |
| Famotidine | Famotidine | 60 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 58 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 58 | 20 |
| Tramadol Hcl | Tramadol Hcl | 56 | 13 |
| Farxiga | Dapagliflozin Propanediol | 55 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 18 |
| Methylprednisolone | Methylprednisolone | 51 | 38 |
| Sertraline Hcl | Sertraline Hcl | 51 | 15 |
| Carvedilol | Carvedilol | 50 | 14 |
| Prednisone | Prednisone | 50 | 34 |
| Allopurinol | Allopurinol | 44 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 14 |
| Eliquis | Apixaban | 44 | suppressed |
| Jardiance | Empagliflozin | 44 | suppressed |
| Hydrocortisone | Hydrocortisone | 42 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 12 |
| Montelukast Sodium | Montelukast Sodium | 40 | 12 |
| Fluconazole | Fluconazole | 39 | 25 |
| Fenofibrate | Fenofibrate | 37 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Telmisartan | Telmisartan | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Nystatin | Nystatin | 24 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 22 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | 13 |
| Irbesartan | Irbesartan | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 12 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 12 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $145.05 · 7 records | ABBVIE INC. | BREZTRI, ELIQUIS, MINIMED 780G, NURTEC ODT, TRELEGY ELLIPTA, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error